Meet The Speaker: Ofer Toledano
Ahead of the 7th Dermatology Drug Development Summit Europe, we sat down with Ofer Toldedano, Vice President, Research & Development at Sol Gel Technologies, for a deep dive into the critical scientific questions driving the next era of CNS & Inflammation research.
Ofer's insights underscore why 2026 is a pivotal year for CNS research — with dermatology pipelines maturing rapidly into Phase II–III, and gene therapies reaching approval, the focus is shifting towards clinical execution, regulatory readiness, and European access.
Dive into insights below and be sure to secure your pass and join Ofer this May in Amsterdam.
Since joining SolGel in 2004, how have you seen the Dermatology field evolve over this time?
Over the past 20 years the dermatology field evolved dramatically, mainly due to development of the biologics and JAK inhibitors. The acne/rosacea field which was dominant 10-15 years ago is less of an interest for companies now. The same begins now in psoriasis and AD. I believe we will see interesting drugs approved for alopecia, vitiligo and HS in the coming years
What do you think the key milestones have been for the industry, and for yourselves in this time?
Key milestones were always the market size and market share we will be abale to gain but lately we've been also looking at niche areas like rare diseases in order to relief the pain of these patients
What current developments are you most excited about, firstly for yourselves, and secondly from your peers?
As I said, drugs for rare disease patients and most interestingly, drug for disease prevention
What do you see as being the key challenges for us to turn these developments into realities?
The big challenge was and always will be to pass the clinical trials, mainly phase 3.
In the short and long term, what would you say your hopes and expectations are for the future of Dermatology research?
To develop better drugs. Most dermatology drugs, mainly topical drugs, have 40-50% success in clinical studies. You rarely see drugs with 70-80% success rate
And finally, why are you excited for the 7th Dermatology Drug Development Summit Europe?
These summits (in the Europe and the US) always bring interesting ideas that make you think differently on your projects, current, and future. It's always good to see familiar faces with new ideas